北京商报讯(记者王维祎)10月24日，由万耀雄鹰主办的Upet有宠生活展在北京中国国际展览中心(朝阳馆)开幕。本届展会展览规模超1.5万平方米，汇集了 120余家国际国内品牌，首日吸引超过两万人次专业观众与养宠家庭参与。 随着小众萌宠市场的强势崛起，展会期间接连举办EPCC国际鹦鹉大赛、SRBA国际品种兔锦标赛及天竺鼠趣味赛事等多项活动。此外，展会还专设了爬宠 等小众异宠专区，集中展示各类特色宠物及专业养护装备，充分展现宠物世界的多元魅力。 本届展会还与北京宠物时装周联动，举办多场人宠时尚秀，展现宠物潮流服饰与个性配饰。据主办方介绍，Upet有宠生活展将持续以北京为起点，辐射全国 核心城市群，整合渠道资源、品牌力量与内容生态，致力于搭建宠物产业的长期价值平台，推动中国宠物行业向专业化、国际化与可持续化方向发展。 ...

Core Insights - The company reported Q3 revenue of 1.517 billion yuan, representing a year-over-year increase of 21.85% but a quarter-over-quarter decrease of 12.88% [1] - The net profit attributable to the parent company for Q3 was 135 million yuan, showing a year-over-year decline of 16.65% and a quarter-over-quarter decline of 22.35% [1] - For the first three quarters of 2025, the company achieved revenue of 4.737 billion yuan, a year-over-year increase of 29.03%, and a net profit of 513 million yuan, up 9.05% year-over-year [1] Revenue Breakdown - Domestic revenue maintained rapid growth, with Q3 domestic business revenue estimated to have increased by over 35%, and the self-owned brand growth exceeding 40% [1] - The company's gross margin in the domestic market is expected to continue improving due to brand premiumization [1] - International revenue is estimated to have declined by approximately 5%-7% in Q3, primarily due to tariff impacts [1] Margin and Expense Analysis - The gross margin for Q3 was 42.92%, showing a year-over-year increase of 1.09 percentage points, but a slight quarter-over-quarter decrease of 0.89 percentage points [2] - The expense ratio for Q3 was 31.07%, up 5.05 percentage points year-over-year, with sales expenses increasing by 52% [2] - Sales, management, and R&D expense ratios were 23%, 6.3%, and 1.4% respectively, with sales expenses driven by the growth of self-owned brands and increased promotional activities [2] Profit Forecast and Valuation - The company's net profit forecasts for 2025-2027 have been revised down by 5.88%, 8.11%, and 11.37% to 706 million yuan, 886 million yuan, and 1.112 billion yuan respectively [3] - The estimated EPS for 2026 is projected at 2.21 yuan, with a target price adjustment to 110.5 yuan, reflecting a 50X PE valuation for 2026 [3] - The company is recognized for its efficient organizational structure and strong core competitive advantages, particularly in the domestic self-owned brand market [3]

Investment Rating - The report assigns a "Buy" rating to the company with a target price of 8.96 CNY over the next six months, up from the previous rating [1][10]. Core Insights - The company has shown significant performance recovery, with a notable increase in revenue and net profit driven by its pet business and ongoing research and development efforts [1][7]. - The revenue for the first half of 2025 reached 2.793 billion CNY, reflecting a year-on-year growth of 12.63%, while the net profit attributable to the parent company was 82 million CNY, up 30.19% year-on-year [7]. - The company is focusing on large customer development and synergistic services in the animal health sector, which is expected to enhance its profitability [7]. Financial Performance Summary - Revenue projections for 2024A, 2025E, 2026E, and 2027E are 6,017 million CNY, 6,569 million CNY, 7,190 million CNY, and 7,798 million CNY respectively, with growth rates of 11.30%, 9.17%, 9.46%, and 8.46% [2][9]. - The net profit attributable to the parent company is forecasted to be 71 million CNY in 2024A, increasing to 287 million CNY in 2025E, 351 million CNY in 2026E, and 386 million CNY in 2027E, with growth rates of -82.41%, 305.33%, 22.12%, and 9.99% respectively [2][9]. - The company’s earnings per share (EPS) are projected to be 0.07 CNY in 2024A, rising to 0.28 CNY in 2025E, 0.34 CNY in 2026E, and 0.38 CNY in 2027E [2][9]. Business Segment Performance - The pharmaceutical segment reported strong performance with sales revenue of 999 million CNY, while the biological products segment faced a decline in revenue to 450 million CNY due to increased competition [7]. - The feed segment generated revenue of 536 million CNY, indicating stable performance despite some pricing pressures [7]. - The company is actively investing in the pet health product market, with significant advancements in product development and brand promotion [7]. Research and Development - The company invested 60 million CNY in R&D in the first half of 2025, representing a year-on-year increase of 4.73%, with a research expense ratio of 2.14% [7]. - The company is focusing on developing vaccines and pharmaceuticals for pets, with several new products launched during the reporting period [7]. Valuation and Market Position - The company is valued at a PE ratio of 32 times for 2025, which is competitive compared to its peers in the animal health industry, which have an average PE of 31 times [10][11]. - The company’s market capitalization is approximately 7.577 billion CNY, with a total asset value of 8.882 billion CNY [5].

Group 1: Company Overview - Hangzhou Tianyuan Pet Products Co., Ltd. focuses on the design, development, production, and sales of pet products and food, covering various categories such as pet bedding, climbing frames, toys, electronic products, clothing, and leashes [2][3]. Group 2: Financial Performance - In 2024, the company achieved a revenue of CNY 2.764 billion, a year-on-year increase of 35.69%. Pet products generated CNY 1.530 billion (up 15.08%, 55.36% of total revenue), while pet food reached CNY 1.176 billion (up 70.80%, 42.55% of total revenue) [3]. - Revenue from overseas markets was CNY 1.332 billion (up 18.40%, 48.20% of total revenue), while domestic revenue was CNY 1.431 billion (up 57.30%, 51.80% of total revenue) [3]. Group 3: Production and Supply Chain - The company has established its own production lines for cat climbing frames and pet bedding, gradually expanding to include toys, clothing, and other pet products, focusing on high-value business segments like product design and supply chain management [3][4]. - Overseas production bases have been set up in Cambodia and Vietnam, while domestic production lines for pet clothing and electronic products have also been established [4]. Group 4: Market Strategy and Brand Development - The company aims to leverage pet food sales to drive the expansion of pet product channels, with brands like "New Food Era" and "Tianyuan It World" focusing on pet food, and five main brands for pet products [5]. - The current revenue contribution from self-owned brands is low, but the company plans to enhance channel construction and e-commerce capabilities to strengthen brand operations [5]. Group 5: Acquisition Progress - As of March 2025, the company is in the process of acquiring Taotong Technology, with ongoing audits and evaluations. The transaction requires further approval from the board and shareholders, as well as regulatory bodies [6][7].